ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,054.48
-0.32%
US Tech 100
17,068.40
0.39%
Dow Jones
38,331.28
-0.45%
Brent Oil
86.945
-0.71%
Bitcoin
64,660.05
-2.64%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Taysha Gene Therapies Inc (TSHA) Quote

Taysha Gene Therapies Inc

Taysha Gene Therapies Inc (TSHA)

NASDAQ
2.4008
-0.1292
( -5.11% )
Updated: 11:37:44
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.4008
Bid
2.40
Ask
2.41
Volume
234,485
2.40 Day's Range 2.54
0.50 52 Week Range 3.89
Market Cap
450.574M
Previous Close
2.53
Open
2.53
Last Trade
5
@
2.401
Last Trade Time
11:38:07
Financial Volume
$ 578,992
VWAP
2.4692
Average Volume (3m)
2,950,317
Shares Outstanding
186,960,193
Dividend Yield
-
PE Ratio
-4.04
Earnings Per Share (EPS)
-0.6
Revenue
15.45M
Net Profit
-111.57M

About Taysha Gene Therapies Inc

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and com... Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.tayshagtx.com
Headquarters
Dover, Delaware, USA
Founded
1970
Taysha Gene Therapies Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TSHA. The last closing price for Taysha Gene Therapies was $2.53. Over the last year, Taysha Gene Therapies shares have traded in a share price range of $ 0.50 to $ 3.89.

Taysha Gene Therapies currently has 186,960,193 shares outstanding. The market capitalization of Taysha Gene Therapies is $450.57 million. Taysha Gene Therapies has a price to earnings ratio (PE ratio) of -4.04.

TSHA Latest News

More News

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies...

April 05 2024
GlobeNewswire Inc.

Another Biotech Steals The Show Following Major Clinical Data Release

There was some pretty substantial news coming out of Dallas, TX this morning after a biotech company shared initial clinical data from the first pediatric patient from the REVEAL To read the full...

March 20 2024
AllPennyStocks.com

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained...

March 19 2024
GlobeNewswire Inc.

US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat

In Tuesday’s pre-market trading, U.S. index futures are pointing to a decline, reflecting investors’ caution as they analyze revelations from Nvidia’s artificial intelligence...

March 19 2024
IH Market News

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing...

March 14 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies...

March 01 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company’s request to initiate dose escalation; dosing of first...

February 29 2024
GlobeNewswire Inc.

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing...

February 15 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 09 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1792-6.945736434112.582.612.1900516147552.41658197CS
4-0.6392-21.02631578953.043.42.1900521681202.83464489CS
120.900860.05333333331.53.551.4129503172.64980563CS
260.20089.127272727272.23.551.2725278262.23833478CS
521.6818233.9082058410.7193.890.526571042.27994006CS
156-20.5392-89.534437663522.9426.990.512424452.89734751CS
260-19.8492-89.209887640422.2533.840.510597443.32242678CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.3648
(139.53%)
132.3M
BOFBranchOut Food Inc
$ 2.09
(78.63%)
68.14M
AMSTAmesite Inc
$ 3.13
(56.50%)
62.01M
MULNMullen Automotive Inc
$ 4.08
(49.45%)
8.89M
LICNLichen China Limited
$ 0.8227
(46.91%)
12.14M
NCINeo Concept International Group Holdings Ltd
$ 5.33
(-43.89%)
1.55M
ISUNiSun Inc
$ 0.0865
(-41.95%)
2.68M
GCTKGlucoTrack Inc
$ 0.447899
(-41.07%)
1.07M
EVOEvotec SE
$ 5.21
(-31.90%)
846.89k
ATXIAvenue Therapeutics Inc
$ 0.094999
(-29.11%)
7.34M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.3648
(139.53%)
132.3M
TSLATesla Inc
$ 161.03
(11.30%)
101.71M
BOFBranchOut Food Inc
$ 2.09
(78.63%)
68.14M
SQQQProShares UltraPro Short QQQ
$ 11.78
(-1.09%)
63.05M
AMSTAmesite Inc
$ 3.13
(56.50%)
62.01M

TSHA Discussion

View Posts
glenn1919 glenn1919 1 month ago
TSHA..............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
TSHA..READY TO PUSH TO 4.00
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
TSHA...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA..here we go
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA NEXT BIO BEAST TO RUN TO 3.61 WATCH THE MAGIC
👍️0
FooBarAndGrill FooBarAndGrill 3 months ago
“Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome. We are pleased with our progress on expanding the study of TSHA-102 across a broad population of ages and stages of Rett syndrome to bring a potentially transformative treatment option to all patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha. “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease. We also plan to expand our U.S. pediatric trial into the U.K. following the recent acceptance of our CTA by the MHRA.”
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
Estimated Enrollment : 18 participants
(was 12).
https://classic.clinicaltrials.gov/ct2/show/NCT05606614
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
“Following review of the initial clinical data from the first two adult patients treated with TSHA-102 and Chemistry, Manufacturing, and Controls (CMC) data, Health Canada has authorized our protocol amendment to include adolescent patients aged 12 years and older in the ongoing REVEAL Phase 1/2 adult trial,”
https://ih.advfn.com/stock-market/NASDAQ/taysha-gene-therapies-TSHA/stock-news/92678004/taysha-gene-therapies-announces-expanded-eligibili
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
The P1 TSHA-102 REVEAL Adult Study has been on a slow boat.
Hopefully, the Clinical Updates PR will give the push to finally complete enrollment of the 12 adult female Rett patients needed for the trial.
I'm guessing reluctance to enroll has been based on the one-time injection into the intrathecal space (directly into the Cerebral Spinal Fluid).
It's definitely worth the risk, IMO. Good Luck to All.
👍️0
bikaver bikaver 7 months ago
TSHA.....Definitely headed in the right direction now. A couple more days of downward momo would be great.
👍️0
make it happen make it happen 7 months ago
Cannacord Genuity and Truist Securities both lowered there price targets, never a good thing...
👍️0
make it happen make it happen 7 months ago
Think it's about there. I believe we flush under $3.00 and don't come back to the this price per share PPS till R/S. A ways away but see it happening. JMHO
👍️0
bikaver bikaver 7 months ago
TSHA.....kicking my butt.....next week is make or break!
👍️0
Triple nickle Triple nickle 8 months ago
Good call my .90 are looking ripe
👍️0
bikaver bikaver 8 months ago
Added 3.28 today.
👍️0
bikaver bikaver 8 months ago
TSHA.....Today, all day, was a bull trap. Tomorrow could be Free Falling Friday.
👍️0
bikaver bikaver 8 months ago
TSHA.....The buyers at 2.85-2.91 proves the phrase "There's a sucker born every minute." to be true.
👍️0
richme richme 8 months ago
Looks like the rocket exploded! Was tempted to buy; glad I did not!

Finally bought 2.19 for 6K shares; too soon; down more now to 2.14.
👍️0
Jess070283 Jess070283 8 months ago
Blast off at open?
👍️0
riha riha 8 months ago
at least i don't feel foolish now.

tomorrow though... i might.
👍️0
alchemytrader alchemytrader 8 months ago
be glad you didnt get any. hit 2.91 a/h.
👍️0
alchemytrader alchemytrader 8 months ago
2.85 RIP
👍️0
Triple nickle Triple nickle 8 months ago
Tif function
👍️0
riha riha 8 months ago
I can't get any shorts... fuck
👍️0
bikaver bikaver 8 months ago
TSHA..... added 2.10 short into this strong close.
👍️0
bikaver bikaver 8 months ago
TSHA.....short @ 1.79
👍️0
snave599 snave599 8 months ago
Because it's up 130%.That's why it's halted.
👍️0
Romiman Romiman 8 months ago
Halted 2 times already this morning
👍️0
make it happen make it happen 8 months ago
Hundreds of millions of shares being sold for $0.90 share structure is multiplying time over 3 massive dilution imho
👍️0
Awl416 Awl416 8 months ago
Taysha Gene Therapies Announces $150 Million Private Placement Financing
👍️0
ErnieBilco ErnieBilco 1 year ago
Between November 2022 and Feb 9th FMR LLC has shed over 700K shares.
👍️0
conix conix 1 year ago
Perspective

https://seekingalpha.com/article/4575072-taysha-fda-stuck-major-blow-to-plans?mailingid=30466606&messageid=2850&serial=30466606.1106
👍️0
ErnieBilco ErnieBilco 1 year ago
What a buying opportunity here this morning.
👍️0
scotsand scotsand 1 year ago
Grabbed more earlier today after doing further due diligence. Glta
👍️0
1hot toddy 1hot toddy 1 year ago
14,000 SHARE BUY @2.21 HUGE BUYS COMING IN $$$$$$$$$$$$$$$$$$$$$$$
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 1 year ago
Thanks, Yeah bios suck that way, ATMs If you want to know my history, here is a recent post, you should see the details of this conversation:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170277591
👍️0
scotsand scotsand 1 year ago
Beating down this morning
👍️0
MiamiGent MiamiGent 1 year ago
Good luck, TA , These bios always put us on edge.

I'm similiarly in "high" on today's bio runner and I could use a drink! lol But I can't because I have to do my business accounting, tonight. Those two don't mix, lol

I was within 2 or 3 cents or stopping myself out and then it zoomed again. Crazy bios

Be strong.. and smart.
👍️0
subslover subslover 1 year ago
That is good your out. I can almost guarantee class action lawsuits for misleading the public.
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 1 year ago
Yeah I'm out. Insider Financial people, Alex or whoever are a bunch of idiots!
👍️0
subslover subslover 1 year ago
aysha Drops on Stock Offering
October 26 2022 - 08:18AM
TipRanks
Alert
Print
Share On Facebook
Gene therapy company Taysha Gene Therapies’ (NASDAQ:TSHA) shares are tanking in the pre-market session today on the announcement of an underwritten public offering of $30 million. All the shares on offer are being sold by Taysha and underwriters will have the option to acquire an additional 15% of shares at the same terms over the next 30 days. The development comes fresh on the heels of Taysha announcing a major deal with Astellas Pharma that will see the latter making a $50 million strategic investment in Taysha for a 15% stake.
https://www.tipranks.com/news/taysha-drops-on-stock-offering?utm_source=advfn.com&utm_medium=referral
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 1 year ago
What I'm not understanding is this Subs: Insider Financial claims Taysha has cancelled an offering but yesterday's PR indicates they are not! Which is it?
👍️0
TechnicalAnalyst1984 TechnicalAnalyst1984 1 year ago
I usually do not touch bio tech companies but took a chance with this one picking up 9387 shares at $2.45 this morning; we'll see
👍️0
subslover subslover 1 year ago
HOD was $3.00 enormous move
👍️0
subslover subslover 1 year ago
HOD was $3.00 enormous move
👍️0
KOmani KOmani 1 year ago
Always happens these days.

You have to trade with the reality that it happens 90% of the time.

However, there wasn't much of a flush at the end of the day.

Have to wonder if it wasn't pre-sold this time.
👍️0
KOmani KOmani 1 year ago
Always a stock offering.

Experience tells me to sell most on any of these big run days.

At least there is no crappy warrants this time around.
👍️0
retireat40 retireat40 1 year ago
Offering. POS
👍️0

Your Recent History

NASDAQ
TSHA
Taysha Gene Therapies
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved